Nadolol
- Generic Name
- Nadolol
- Brand Names
- Corgard
- Drug Type
- Small Molecule
- Chemical Formula
- C17H27NO4
- CAS Number
- 42200-33-9
- Unique Ingredient Identifier
- FEN504330V
- Background
Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure. Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects.
Nadolol was granted FDA approval on 10 December 1979.
- Indication
Nadolol is indicated to treat angina pectoris and hypertension. Another product formulated with bendroflumethiazide is indicated to treat hypertension.
- Associated Conditions
- Angina Pectoris, Atrial Fibrillation, Gastroesophageal variceal hemorrhage prophylaxis, Hypertension, Migraine, Thyrotoxicosis
Phase 3 Trial Shows Promising Results for Novel Encapsulated Cell Therapy in MacTel Treatment
• Phase 3 clinical trials of NT-501, an encapsulated cell therapy delivering CNTF, demonstrated significant reduction in disease progression for macular telangiectasia type 2 patients, with up to 52% reduction in ellipsoid zone loss.
• The innovative implantable device, developed by Neurotech, maintains long-term viability with CNTF production documented for up to 14.5 years, offering a potential alternative to frequent intravitreal injections.
• FDA review of the therapy is currently underway with a PDUFA date set for March 18, 2025, marking a potential breakthrough in MacTel treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath